NDA 215092 · Ocuvex Therap
Omlonti
Omidenepag Isopropyl · Ophthalmic
NovelCDER novel approval, Sep 22, 2022: To reduce elevated intraocular pressure in patients with open‑angle glaucoma or ocular hypertension
Last checked: Nov 20, 2026Latest source record: Sep 22, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Sep 22, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 0 recruiting
FAERS reports
66
64 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 21, 2025.
Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, is a relatively selective prostaglandin E2 (EP2) receptor agonist, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. ( 1 )
Mechanism: Omidenepag is a relatively selective EP2 receptor agonist which decreases intraocular pressure (IOP). The exact mechanism of action is unknown at this time. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
Therapeutic areas: Cardiovascular and metabolic · Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- OMLONTI · OMIDENEPAG ISOPROPYL 0.002% · SOLUTION, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Omidenepag Isopropyl" as an intervention, any sponsor and status, largest first.
- Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag IsopropylStatus unknown
Santen Pharmaceutical Asia Pte. Ltd.Industry
NCT05279716 · 150 participants (planned) · Start Feb 15, 2022 · Primary completion Dec 8, 2022
Drug: Eybelis ophthalmic solution 0.002% · For: Normal Tension Glaucoma; Primary Open-angle Glaucoma; Glaucoma, Suspect and 1 more
Sites: Seongnam-si, South Korea; Seoul, South Korea · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- cataract20
- contraindicated product administered9
- intercepted product prescribing error6
- cystoid macular oedema5
- intraocular pressure increased5
- anaphylactic reaction4
- glaucoma4
- macular oedema4
- uveitis4
- vision blurred4
- ocular hyperaemia3
- refraction disorder3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 1 |
| 2023 | 12 |
| 2024 | 21 |
| 2025 | 18 |
| 2026 | 14 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and Efficacy of Omidenepag Isopropyl for Elevated Intraocular Pressure: A Systematic Review and Meta-Analysis.
Sharma S, Singh R, Balas M, et al. · Am J Ophthalmol 2025 · Meta-Analysis, Systematic Review
- Clinical Efficacy of Omidenepag Isopropyl for Primary Open-Angle Glaucoma, Normal Tension Glaucoma, or Ocular Hypertension: A Meta-Analysis.
Kuo HT, Yeh CY, Hsu AY, et al. · J Ocul Pharmacol Ther 2023 · Systematic Review, Meta-Analysis
- Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study).
Aihara M, Lu F, Kawata H, et al. · J Ocul Pharmacol Ther 2019 · Clinical Trial, Phase I, Randomized Controlled Trial
- Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3).
Bacharach J, Brubaker JW, Evans DG, et al. · Am J Ophthalmol 2024 · Clinical Trial, Phase III, Multicenter Study
- Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
Aihara M, Ropo A, Lu F, et al. · Jpn J Ophthalmol 2020 · Clinical Trial, Phase III, Multicenter Study
- Omidenepag Isopropyl in Latanoprost Low/Nonresponders With Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 3, Nonrandomized, Two-Phase, Open-Label Study.
Panarelli JF, Bowden EC, Tepedino ME, et al. · J Glaucoma 2023 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Ocuvex Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.